Subcutaneous immunoglobulin: Facilitated infusion and advances in administration

Clinical and Experimental Immunology

Volumn 178, Issue S1, 2014, Pages 75-77

  Wasserman, R L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; RECOMBINANT HYALURONIDASE;

ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYDRAULIC CONDUCTIVITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; MIGRAINE; MOUTH PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; ADVERSE EFFECTS; CLINICAL TRIAL; COMPARATIVE STUDY; MULTICENTER STUDY; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; PROSPECTIVE STUDIES;

EID: 84921524484     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12519     Document Type: Article

References (7)

1. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:1-7.
2. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779-802.
3. Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 2014; 6:553-567.
4. Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013; 111:51-55.
5. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4:427-440.
6. Wasserman RL, Melamed I, Stein MR etal. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130:951-957 e11.
7. Melamed I, Wasserman R, Stein MR etal. Long-term safety and pharmacokinetics of facilitated-subcutaneous infusion of human immune globulin G, 10%, and recombinant human hyaluronidase: phase 3 extension study in patients with primary immunodeficiencies. Poster P213 presented at the American College of Allergy, Asthma and Immunology Meeting, 2012.